[
  {
    "ts": null,
    "headline": "ACHV: Achieve’s Busy Day",
    "summary": "By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted a flurry of press releases last week announcing the submission of its new drug application (NDA), a partnership with Omnicom for cytisinicline commercialization, a proposed public offering and the pricing of the offering. The capital raise was closed on June 30 th . This is",
    "url": "https://finnhub.io/api/news?id=fc7b0dbbfcf8662c378ae5ec057ad0d51e03f7cceea62255732d968cabe9a2e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751534160,
      "headline": "ACHV: Achieve’s Busy Day",
      "id": 135736554,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "OMC",
      "source": "Yahoo",
      "summary": "By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted a flurry of press releases last week announcing the submission of its new drug application (NDA), a partnership with Omnicom for cytisinicline commercialization, a proposed public offering and the pricing of the offering. The capital raise was closed on June 30 th . This is",
      "url": "https://finnhub.io/api/news?id=fc7b0dbbfcf8662c378ae5ec057ad0d51e03f7cceea62255732d968cabe9a2e4"
    }
  }
]